Table 1:

Baseline characteristics of people who inject drugs enrolled in the Montreal Hepatitis C Cohort (2004–2017), by prescribed dosage of opioid agonist treatment, categorized according to clinical guideline recommendations* and patient-perceived dosage adequacy

CharacteristicDosage of opioid agonist treatment and perceived adequacy; no. (%) of participantsp value
Not enrolled in opioid agonist treatment
n = 354
High dosage, perceived adequate
n = 61
High dosage, perceived inadequate
n = 25
Low dosage, perceived adequate
n = 49
Low dosage, perceived inadequate
n = 24
Age, yr, mean (± SD)35.8 (± 10.8)39.5 (± 10.7)38.4 (± 9.6)34.9 (± 9.7)32.3 (± 7.9)0.02
Age, yr, median (IQR)33.9 (26.9–44.3)40.7 (31.1–47.3)37.5 (32.2–43.0)33.3 (27.4–42.3)31.3 (26.7–35.6)0.03
Sex, male284 (80.2)43 (70.5)16 (64.0)36 (73.5)19 (79.2)0.3
College education or higher74 (20.9)22 (36.1)10 (40.0)13 (26.5)11 (45.8)< 0.01
Duration of injection drug use, yr, mean (± SD)11.0 (± 10.2)18.2 (± 9.4)16.5 (± 11.5)13.4 (± 9.9)11.6 (± 8.8)< 0.01
Duration of injection drug use, yr, median (IQR)7.8 (2.8–16.2)18.0 (10.1–26.1)15.0 (4.7–25.0)12.3 (4.6–20.3)9.7 (4.0–16.1)< 0.01
Opioids injection, past mo260 (73.4)33 (54.1)22 (88.0)37 (75.5)22 (91.7)< 0.01
Cocaine injection, past mo191 (54.0)28 (45.9)8 (32.0)25 (51.0)11 (45.8)< 0.01
High frequency of injection drug use (≥ 30 injections), past mo208 (58.8)20 (32.8)13 (52.0)22 (44.9)19 (79.2)< 0.01
Unstable housing, past mo147 (41.5)16 (26.2)4 (16.0)8 (16.3)7 (29.2)< 0.01
Incarceration, past 3 or 6 mo§76 (21.5)12 (19.7)5 (20.0)9 (18.4)7 (29.2)0.9
Previous HCV infection76 (21.5)34 (55.7)14 (56.0)25 (51.0)9 (37.5)< 0.01
2004–2011 follow-up wave (v. 2011–2017)199 (56.2)21 (34.4)12 (48.0)27 (55.1)10 (41.7)0.02
  • Note: HCV = hepatitis C virus, IQR = interquartile range, SD = standard deviation.

  • * Prescribed dosage was categorized as high if methadone ≥ 60 mg/d or buprenorphine ≥ 16 mg/d, and low otherwise. (3), (5) (7)

  • Unless stated otherwise.

  • p value derived from analysis of variance and Kruskal–Wallis test for age and duration of injection, and χ2 test for all other variables.

  • § Depending on follow-up wave.